Pasar al contenido principal

Resultados de investigación

Rights
Projectcode
Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
oai:repositoriosaludmadrid.es:20.500.12530/146654
Datos de investigación Set de datos (Dataset)

Niveles de galectina 1 y galectina 9 en enfermedades mediadas por mecanismos inmunes

Levels of galectin 1 and galectin 9 in immune-mediated diseases
  • Valero Martínez, Cristina
  • Pardines Ortiz, Marisa
  • Montes Casado, Nuria
  • Daudén Tello, Esteban
  • Fernández Gutiérrez, Benjamín
  • García Planella, Esther
  • Gomollón Garcia, Fernando
  • Gratacos, Jordi
  • Pérez Venegas, José Javier
  • Julia, Antonio
  • Marsal, Sara
  • Lamana Dominguez, Amalia
  • García de Vicuña Pinedo, Rosario
  • González Alvaro, Isidoro
  • Triguero Martínez, Ana
Galectin-1 and -9 (Gal1/9) are essential mediators of immune-inflammatory responses, which makes these proteins potential biomarkers for immune-mediated diseases (IMIDs), such as rheumatoid arthritis (RA), psoriasis (PS), psoriatic arthritis (PsA), inflammatory bowel disease, and systemic lupus erythematosus (SLE). Our aim was to evaluate plasma Gal1/9 differences between IMID patients and healthy donors (HD). We analyzed 980 plasma samples divided into two analytical cohorts (600 discovery group and 380 validation group). Generalized linear models estimated Gal1/9 levels, adjusting for sex, age, storage time, and plate variability. In the overall IMID group, plasma Gal1 levels were comparable to those of HD, while Gal9 levels were significantly elevated. Levels varied across individual diseases: SLE patients consistently showed the highest Gal1/9 levels compared to both HD and other IMIDs, and RA patients had elevated Gal9 levels versus HD. Both Gal1 and Gal9 plasma levels correlated positively with higher disease activity, and Gal1 was higher in patients with longer disease duration. After adjustment for these confounders, SLE and RA patients maintained the highest Gal9 levels compared to HD. Our study demonstrates that Gal1 and Gal9 are differentially expressed across IMIDs, with particularly elevated levels in SLE, and both galectins are associated with disease activity.
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
oai:repositoriosaludmadrid.es:20.500.12530/131642
Datos de investigación Set de datos (Dataset)

Acute Gluten-Induced Inflammatory Protein Signature in Celiac Disease: A Step Towards Biomarker Discovery

Firma proteica inflamatoria inducida agudamente por el gluten en la enfermedad celíaca: un paso hacia el descubrimiento de biomarcadores
  • Gómez Aguililla, Sara
  • Farrais Villalba, Sergio
  • López Palacios, Natalia
  • Arau, Beatriz
  • Senosiain, Carla
  • Infante Menéndez, Jorge
  • Ruiz Carnicer, Ángela
  • Fernández Bañares, Fernando
  • González López, Nuria
  • Pujals, Mar
  • Sousa, Carolina
  • Núñez Pardo de Vera, María Concepción
Relative concentrations of 74 inflammation-related serum proteins obtained by proximity extension assay (PEA, Olink) in patients with celiac disease and in non-celiac controls. Measurements were obtained while participants were on a gluten-free diet (≥1 month) at two time points: baseline (on GFD) and 4 hours after a single gluten challenge (10 g). NA indicates values below the limit of quantification., Background Diagnosis of celiac disease (CD) remains challenging in individuals already on a gluten-free diet (GFD). Although several alternative methods have been proposed, they have limitations. Identifying inflammation-related proteins that rapidly respond to gluten exposure in blood may offer diagnostic alternatives. Objective To characterize the inflammatory protein response to gluten in patients with CD on a GFD, and to assess the diagnostic potential of candidate biomarkers and their association with clinical symptoms. Methods Seventeen patients with CD and 15 non-CD individuals on a GFD (≥ 1 month) consumed 10 g of gluten. Serum, plasma and clinical symptoms were collected at baseline and 4 h post-gluten ingestion to assess changes in 92 inflammation-related proteins. Results Following gluten consumption, 18 proteins changed significantly only in patients with CD. Six showed an AUC ≥80%, and CCL20 achieved 85.7% sensitivity and 92.7% specificity for CD diagnosis. CCL20 level increases post-gluten challenge were higher in patients with vomiting but were also observed in those with absent or mild symptoms. Conclusion Gluten reintroduction triggers alterations in the inflammation-related protein profile of patients with CD. CCL20 emerges as a promising diagnostic candidate, its increase in plasma or serum, with low dependence on symptom presentation, may complement existing diagnostic approaches., Base de datos
Buscador avanzado